Q32 Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-6.65	6.65	-
Cost of Revenue	48.14	31.73	35.81	29.93
Gross Profit	-48.14	-38.38	-29.16	-29.93
Selling, General & Admin	17.96	9.88	10.06	6.76
Operating Expenses	17.96	9.88	10.06	6.76
Operating Income	-66.1	-48.26	-39.23	-36.69
Interest Expense	-1.4	-2	-	-
Interest & Investment Income	3.9	-	-	-
Earnings From Equity Investments	-1.63	-	-	-
Other Non Operating Income (Expenses)	2.3	3.02	-3.52	-0.32
EBT Excluding Unusual Items	-62.93	-47.23	-42.75	-37.02
Gain (Loss) on Sale of Investments	-0.68	-	-	-
Other Unusual Items	15.89	-6.19	-	-
Pretax Income	-47.71	-53.43	-42.75	-37.02
Income Tax Expense	0.02	0.32	0.06	0.55
Net Income	-47.73	-53.74	-42.81	-37.56
Net Income to Common	-47.73	-53.74	-42.81	-37.56
Shares Outstanding (Basic)	9	0	7	6
Shares Outstanding (Diluted)	10	0	7	6
Shares Change (YoY)	2666.77%	-95.03%	8.57%	-
EPS (Basic)	-5.12	-153.96	-6.09	-5.81
EPS (Diluted)	-6.58	-153.96	-6.09	-5.81
Free Cash Flow	-67.79	-18.68	-13.44	-33.14
Free Cash Flow Per Share	-7.02	-53.52	-1.91	-5.12
Operating Margin	-	-	-589.76%	-
Profit Margin	-	-	-643.65%	-
Free Cash Flow Margin	-	-	-202.10%	-
EBITDA	-65.62	-47.76	-38.86	-36.65
D&A For EBITDA	0.49	0.5	0.37	0.05
EBIT	-66.1	-48.26	-39.23	-36.69

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q